Randomised, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Lu AA24493 in Acute Ischemic Stroke.

Trial Profile

Randomised, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Lu AA24493 in Acute Ischemic Stroke.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Sep 2010

At a glance

  • Drugs Lu AA 24493 (Primary)
  • Indications Stroke
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Dec 2008 End date added from ClinicalTrials.gov.
    • 31 Dec 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top